Heart Failure Therapies following Acute Coronary Syndromes with Reduced Ejection Fraction: Data from the ACSIS Survey

B Zafrir, T Ovdat, M Abu Akel, F Bahouth… - Journal of Personalized …, 2023 - mdpi.com
Background: Guideline-directed medical therapies for heart failure (HF) may benefit patients
with reduced left ventricular ejection fraction (LVEF) following acute coronary syndromes …

[引用][C] Effect Sacubitril/Valsartan in patients with Acute Myocardial Infarction (AMI): a systematic review and meta-analysis

FSM Pratistha, IWS Ardiana - Intisari Sains Medis, 2023

Natriuretic Peptide Guidance for Post-Myocardial Infarction Care: An Opportunity to Prevent Heart Failure Progression

WHW Tang, W Zheng - Circulation: Heart Failure, 2023 - Am Heart Assoc
Over the past 2 decades, natriuretic peptides have earned their rightful place in the
diagnosis and management of heart failure (HF). Clinical guidelines have emphasized the …

[PDF][PDF] 急性心肌梗死患者应用沙库巴曲缬沙坦治疗研究进展

谭慧, 唐关敏 - 心电与循环 - xdyxh.com
沙库巴曲缬沙坦(ARNI) 为新型治疗心力衰竭(下称心衰) 药物, 其将脑啡肽酶抑制剂与血管紧张
素受体拮抗剂相结合, 在治疗射血分数降低的心衰方面, 已被建议作为一线治疗用药 …

MRA indication and underuse in high‐risk post myocardial infarction patients

JP Ferreira, X Rossello, F Zannad - 2023 - policycommons.net
MRA indication and underuse in high-risk post myocardial infarction patients. European
Journal of Heart Failure, 2023, 10.1002/ejhf. 3098.[...]“Sacubitril/valsartan compared to …

[HTML][HTML] The PARADISE‐MI trial: a new opportunity to improve the left ventricular remodelling in reperfused STEMI

A Bellis, C Mauro, E Barbato, B Trimarco… - ESC Heart …, 2022 - ncbi.nlm.nih.gov
The current management of ST-elevation myocardial infarction (STEMI) has reached
remarkable improvement in outcomes through the wide diffusion of early primary …

[HTML][HTML] Impatto della pandemia COVID-19 sui trial clinici in cardiologia

G Di Pasquale, AP Maggioni… - Giornale Italiano di …, 2022 - giornaledicardiologia.it
Con l'inizio della pandemia COVID-19 nel marzo 2020 c'è stata un'esplosione di trial clinici
condotti in pazienti COVID-19. Tranne che in poche eccezioni come gli studi RECOVERY 1 …

The Year in Hungarian Cardiology 2022: Heart failure and cardiomyopathies

T Habon, M Rábai, R Halmosi - Cardiologia Hungarica, 2023 - real.mtak.hu
In the year 2022 a large number of remarkable scientific papers were published in the field
of heart failure and heart muscle disease, to which the Hungarian Heart Failure community …

Mortality and Heart Failure Risk Reductions in Patients Treated With Sacubitril–Valsartan in Clinical Trials

A Cordero, J Nuñez… - American Journal of …, 2022 - journals.lww.com
The angiotensin receptor neprilysin inhibitor sacubitril–valsartan is included in the first-line
treatment for heart failure (HF) and reduced left ventricle ejection fraction (LVEF). 1 …

[PDF][PDF] Terapia farmacológica en insuficiencia cardiaca fracción de eyección reducida:¿ cómo, cuánto, a quién?

I Cañete, A de la Carrera, A Gil, I Orchard… - redclinica.cl
Terapia farmacológica en insuficiencia cardiaca fracción de eyección reducida: ¿cómo,
cuánto, a quién? Page 1 50 Terapia farmacológica en insuficiencia cardiaca fracción de …